a Non-reducing SDS-PAGE of test samples and by Vanessa Radtke (1674097)

MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Comparison of virus fitness of variant rgC-A314G (K73R) and WT. by You-Yuan Tsai (3142086)

Subjects:

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”

Response of I_Ca,L to IBMX in WT and AMPKα2-/- mice AVMs. by Anne Garnier (130125)

Subjects:

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Loss of <i>SLC4A11</i> expression and CHED-associated <i>SLC4A11</i> mutations in hCEnC lead to decreased cell viability during tBH-induced oxidative stress. by Doug D. Chung (3611387)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

Dose-dependent decreases in cell viability with carboplatin, mitoxantrone, vinblastine, and CBD treatment of canine UC cells. by Jordon M. Inkol (11237604)

Minimum quorum sensing inhibitory concentrations (MQSICs), minimum inhibitory concentrations (MICs), and concentrations inhibiting 50% of violacein production (IC50s) of compounds... by Jean Paul Dzoyem (6424445)

Subjects:

Comparison of the ISIs that caused 0%, 50% and 100% decreases in response magnitudes (AI spikes, AI fEPSP and MGBv spikes) to succeeding tone. by Colin Xiong (9182695)

Discrimination performance deteriorated as the safe-to-conditioned ΔF decreased. by Chi Chen (67021)

The S75A mutation of LeishIF4E3 leads to a decrease in granule formation in response to PBS starvation and to a reduced interaction with LeishIF4G-4. by Rohit Shrivastava (6459608)

Lower insular perfusion in the DAT group compared with the non-DAT group. by Masashi Takeuchi (1930312)

“…In the region of interest-based analysis, decrease extent ratios were higher in the DAT group (N = 12) than in the non-DAT group (N = 38) (D). …”

Spatial training decreases endogenous PTEN ubiquitination and <i>Pten</i> cKO mice show impaired spatial learning and memory. by Wei-Lun Hsu (1756123)

“…<p><b>(A)</b> Control siRNA or Nedd4 siRNA (10 pmol) was transfected to the rat CA1 area. …”

Image_2_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Image_1_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”